Drugmakers see $33bn bout of M&A activity http://www.ft.com/intl/cms/s/0/27a0a042-9537-11e1-ad38-00144feab49a.html#axzz1uD9S5R9j A recent spate of takeovers in healthcare, as drugmakers seek to replace expiring drug patents, has made it the busiest sector in April with acquisitions around the world worth more than $33bn, according to Dealogic. Completed transactions included AstraZeneca&rsquo ...

SXC Health to buy Catalyst in deal valued at $4.4B http://finance.yahoo.com/news/sxc-health-buy-catalyst-deal-122324117.html SXC Health Solutions Corp. plans to buy fellow pharmacy benefits manger Catalyst Health Solutions Inc. in a deal the companies valued at $4.4 billion, less than a month after competitor Express Scripts Inc. closed a $29.1 billion acquisition.SXC Health said Wednesday it wi ...

Shire to buy U.S. biotech firm for up to $325 million http://www.reuters.com/article/2012/03/15/us-shire-idUSBRE82E0K520120315 UK drugmaker Shire Plc (SHP.L) said it would buy privately held biotechnology firm FerroKin BioSciences for up to $325 million, including an upfront cash payment of $100 million, to expand its portfolio of blood disease treatments. The deal terms also included potential m ...

Amylin Rejects $3.5 Billion Bid From Bristol; Offer Represents Premium to Firm's Stand-Alo http://torontostar.morningstar.ca/globalhome/industry/news.asp?articleid=542298 Shares of Amylin Pharmaceuticals AMLN skyrocketed Tuesday as it was revealed that the firm rejected a $3.5 billion, or $22 per share, takeout offer from Bristol-Myers Squibb BMY last month. The bid represents a significant ...

B+L to buy drug firm for $500M http://www.democratandchronicle.com/article/20120328/BUSINESS/303280024/Bausch-Lomb-Inc-?odyssey=tab%7Ctopnews%7Ctext%7CBusiness Perhaps coming soon to a pharmacist near you: a new Bausch + Lomb Inc. solution for treating itchy eyes from allergic conjunctivitis, a nasal spray for treating rhinitis allergy symptoms, and a solution to cut glaucoma postoperative pain a ...